7-chloro-4-methyl-2-(methylthio)-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine | 805318-43-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 7-chloro-4-methyl-2-(methylthio)-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
• 英文别名: N,8-dimethyl-2-(methylthio)-5-chloro-8H-imidazo[4.5-d]thiazolo[5,4-b]pyridine；8-Chloro-12-methyl-4-methylsulfanyl-5-thia-3,7,10,12-tetrazatricyclo[7.3.0.02,6]dodeca-1,3,6,8,10-pentaene
• CAS: 805318-43-8
• 化学式: C₉H₇ClN₄S₂
• 分子量: 270.766
• InChiKey: ZQIPVJSQJIPXCH-UHFFFAOYSA-N

物化性质

• 沸点：
  481.6±55.0 °C(Predicted)
• 密度：
  1.76±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  97.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  7-chloro-4-methyl-2-(methylthio)-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine 在 Oxone 、 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 反应 48.0h， 以84%的产率得到8-methyl-2-(methylsulfonyl)-5-chloro-8H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
  参考文献：
  名称：

  Imidazo-fused oxazolo[4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same

  摘要：

  本发明提供了具有以下式（I）的嘧啶嘧啶嘧啶基三环化合物，其中R1、R2、R3和R6如本文所述。本发明还提供包含这种化合物的药物组合物，以及利用这种化合物治疗炎症和免疫性疾病的用途。

  公开号：

  US20060106051A1
• 作为产物：
  描述：

  4,6-二氯-1-甲基-1H-咪唑并[4,5-c]吡啶-7-胺 、 potassium trithiocarbonate 、 碘甲烷 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.5h， 生成 7-chloro-4-methyl-2-(methylthio)-4H-imidazo[4,5-d]thiazolo[5,4-b]pyridine
  参考文献：
  名称：

  Novel Tricyclic Inhibitors of IκB Kinase

  摘要：

  The design and synthesis of a novel series of oxazole-, thiazole-, and imidazole-based inhibitors of I kappa B kinase (IKK) are reported. Biological activity was improved compared to the pyrazolopurine lead, and the expedient synthesis of the new tricyclic systems allowed for efficient exploration of structure-activity relationships. This, combined with an iterative rat cassette dosing strategy, was used to identify compounds with improved pharmacokinetic (PK) profiles to advance for in vivo evaluation.

  DOI：

  10.1021/jm8015816

文献信息

• IMIDAZO-FUSED THIAZOLO [4,5-B] PYRIDINE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
  申请人：Bristol-Myers Squibb Company

  公开号：EP1833836B1

  公开（公告）日：2011-12-21
• US7176214B2
  申请人：——

  公开号：US7176214B2

  公开（公告）日：2007-02-13
• US7456194B2
  申请人：——

  公开号：US7456194B2

  公开（公告）日：2008-11-25
• Imidazo-fused oxazolo[4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
  申请人：Dyckman Alaric

  公开号：US20060106051A1

  公开（公告）日：2006-05-18

  The present invention provides for pyrazolopurine-based tricyclic compounds having the formula (I), wherein R 1 , R 2 , R 3 , and R 6 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.

  本发明提供了具有以下式（I）的嘧啶嘧啶嘧啶基三环化合物，其中R1、R2、R3和R6如本文所述。本发明还提供包含这种化合物的药物组合物，以及利用这种化合物治疗炎症和免疫性疾病的用途。
• Novel Tricyclic Inhibitors of IκB Kinase
  作者：James Kempson、Steven H. Spergel、Junqing Guo、Claude Quesnelle、Patrice Gill、Dominique Belanger、Alaric J. Dyckman、Tianle Li、Scott H. Watterson、Charles M. Langevine、Jagabandhu Das、Robert V. Moquin、Joseph A. Furch、Anne Marinier、Marco Dodier、Alain Martel、David Nirschl、Katy Van Kirk、James R. Burke、Mark A. Pattoli、Kathleen Gillooly、Kim W. McIntyre、Laishun Chen、Zheng Yang、Punit H. Marathe、David Wang-Iverson、John H. Dodd、Murray McKinnon、Joel C. Barrish、William J. Pitts

  DOI：10.1021/jm8015816

  日期：2009.4.9

  The design and synthesis of a novel series of oxazole-, thiazole-, and imidazole-based inhibitors of I kappa B kinase (IKK) are reported. Biological activity was improved compared to the pyrazolopurine lead, and the expedient synthesis of the new tricyclic systems allowed for efficient exploration of structure-activity relationships. This, combined with an iterative rat cassette dosing strategy, was used to identify compounds with improved pharmacokinetic (PK) profiles to advance for in vivo evaluation.